ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Abdessamad El Kaoutari
Matched on ORCID iD 0000-0003-2334-3121; OpenAlex author ID A5037739924. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 2 papers
Papers 9
- Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. Co-author DOI 10.1158/0008-5472.can-22-3219↗
- EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. Co-author DOI 10.1172/jci.insight.173746↗
- Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Co-author DOI 10.1016/j.ebiom.2023.104634↗
- Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
- Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
- A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. First author DOI 10.1016/j.ebiom.2021.103541↗
- Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Co-author DOI 10.3390/cancers13102473↗
- Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100143↗
- Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical s… First author DOI 10.1096/fj.202000363rr↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nelson Dusetti · 9 shared papers, 2020–2024 · strength 1.19
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746↗
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. DOI 10.1158/0008-5472.can-22-3219↗
- Juan Iovanna · 7 shared papers, 2020–2023 · strength 0.87
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Odile Gayet · 6 shared papers, 2020–2023 · strength 0.74
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Julie Roques · 5 shared papers, 2020–2023 · strength 0.63
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Paper A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. DOI 10.1016/j.ebiom.2021.103541↗
- Nicolas Alejandro Fraunhoffer · 3 shared papers, 2021–2023 · strength 0.39
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
- Rémy Nicolle · 3 shared papers, 2020–2021 · strength 0.34
- Paper A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. DOI 10.1016/j.ebiom.2021.103541↗
- Paper Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreat… DOI 10.1096/fj.202000363rr↗
- Paper Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
- Raul A. Urrutia · 2 shared papers, 2021–2024 · strength 0.29
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Gwen Alyce Lomberk · 2 shared papers, 2021–2024 · strength 0.29
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Philippe Soubeyran · 2 shared papers, 2021–2023 · strength 0.29
- Paper Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. DOI 10.1016/j.ebiom.2023.104634↗
- Paper Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. DOI 10.1016/j.ebiom.2021.103332↗
- Nadine Abdel Hadi · 2 shared papers, 2020–2023 · strength 0.24
- Rawand Masoud · 2 shared papers, 2020–2023 · strength 0.24
- Tristan Gicquel · 2 shared papers, 2020–2023 · strength 0.24
- Gabriela Reyes‐Castellanos · 2 shared papers, 2020–2023 · strength 0.24
- Alice Carrier · 2 shared papers, 2020–2023 · strength 0.24
- Owen Hoare · 2 shared papers, 2021 · strength 0.22
- Emilie Jaune · 1 shared paper, 2024 · strength 0.17
- Fatemeh Mousavi · 1 shared paper, 2024 · strength 0.17
- Christopher L. Pin · 1 shared paper, 2024 · strength 0.17
- Yolande Berthois · 1 shared paper, 2023 · strength 0.16
- Jérôme Torrisani · 1 shared paper, 2024 · strength 0.15
- Audrey Lumeau · 1 shared paper, 2024 · strength 0.15
- Guillaume Labrousse · 1 shared paper, 2024 · strength 0.15
- Audrey Francès · 1 shared paper, 2024 · strength 0.15
- Naïma Hanoun · 1 shared paper, 2024 · strength 0.15
- Louis Buscail · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.